Metoject pens replace prefilled syringes

Medac has launched Metoject PEN (methotrexate) a single-use prefilled pen for subcutaneous injection, to replace the existing syringe presentation.

Metoject is no longer indicated for Crohn's disease.
Metoject is no longer indicated for Crohn's disease.

The new prefilled pen device is available in the full range of existing doses and has the same colour coding as the syringe to distinguish between the different strengths.

It is indicated for the treatment of:

  • severe recalcitrant disabling psoriasis
  • severe psoriatic arthritis
  • polyarthritic forms of severe active juvenile idiopathic arthritis when the response to NSAIDs has been inadequate
  • active rheumatoid arthritis.

The Metoject pen device is not currently licensed for use in Crohn's disease.

View Metoject drug record

Further information: Medac

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.